Skip to main content
Premium Trial:

Request an Annual Quote

Bruker s Q3 Receipts Grow 6.3 Percent as Firm Posts Profit; Daltonics, AXS Post Revenue Gains

NEW YORK, Nov. 3 (GenomeWeb News) - Bruker BioSciences yesterday posted a profit in the third quarter as revenues increased 6.3 percent and R&D spending fell slightly.


Total receipts for the three months ended Sept. 30 increased to $70.7 million from $66.5 million year over year.   Revenue from products increased 4.4 percent to $61 million in the quarter, service receipts improved 1.7 percent in the quarter to $8.7 million, and other revenues jumped 46 percent to $928,000, the company said.


Bruker said that third quarter revenues from its Daltonics division jumped 7.8 percent year over year to $36.9 million, while receipts for its AXS business increased 4.9 percent to $33.9 million.


Third-quarter R&D spending declined to just under $10 million from $10.8 million in the year-ago period.


Bruker also posted a net profit of $1 million, or $.01 per share, from a net loss of $3 million, or $.03 per share, in last year's third quarter.


Bruker said it had around $95.3 million in cash and short-term investments as of Sept. 30.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.